Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review.
Pablo Redruello-GuerreroPaula Córdoba-PeláezAntonio Jesús Láinez Ramos-BossiniMario RiveraCristina MesasRaúl OrtizJose Carlos PradosGloria PerazzoliPublished in: Current drug delivery (2024)
significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.
Keyphrases
- systematic review
- small cell lung cancer
- clinical trial
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- advanced non small cell lung cancer
- prognostic factors
- signaling pathway
- drug delivery
- meta analyses
- peritoneal dialysis
- big data
- machine learning
- patient reported outcomes
- artificial intelligence
- deep learning
- free survival